Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

BACKGROUND: The Janus kinase/signal transducer and activator of transcription (JAK‐STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regora...

Descripción completa

Detalles Bibliográficos
Autores principales: Fogelman, David, Cubillo, Antonio, García‐Alfonso, Pilar, Mirón, María Luisa Limón, Nemunaitis, John, Flora, Daniel, Borg, Christophe, Mineur, Laurent, Vieitez, Jose M., Cohn, Allen, Saylors, Gene, Assad, Albert, Switzky, Julie, Zhou, Li, Bendell, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246927/
https://www.ncbi.nlm.nih.gov/pubmed/30123970
http://dx.doi.org/10.1002/cam4.1703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246927/
https://www.ncbi.nlm.nih.gov/pubmed/30123970
http://dx.doi.org/10.1002/cam4.1703

Ejemplares similares